Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
2.

The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review.

Bosschieter J, Lutz C, Segerink LI, Vis AN, Zwarthoff EC, A van Moorselaar RJ, van Rhijn BW, Heymans MW, Jansma EP, Steenbergen RD, Nieuwenhuijzen JA.

Epigenomics. 2018 May;10(5):673-687. doi: 10.2217/epi-2017-0156. Epub 2018 Apr 25.

PMID:
29692199
3.

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.

van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC.

Clin Cancer Res. 2018 Apr 1;24(7):1586-1593. doi: 10.1158/1078-0432.CCR-17-2719. Epub 2018 Jan 24.

PMID:
29367430
4.

Analysis of Point Mutations in Clinical Samples of Urothelial Carcinoma.

Alamyar M, Zwarthoff EC.

Methods Mol Biol. 2018;1655:19-28. doi: 10.1007/978-1-4939-7234-0_2.

PMID:
28889374
5.

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.

Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF.

Eur Urol. 2017 Sep;72(3):461-469. doi: 10.1016/j.eururo.2017.05.040. Epub 2017 Jun 2.

PMID:
28583312
6.

Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer.

Smedinga H, Steyerberg EW, Beukers W, van Klaveren D, Zwarthoff EC, Vergouwe Y.

Am J Epidemiol. 2017 Sep 1;186(5):612-623. doi: 10.1093/aje/kwx133.

PMID:
28525539
7.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC.

Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5.

PMID:
28390739
8.

A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.

van Kessel KE, van de Werken HJ, Lurkin I, Ziel-van der Made AC, Zwarthoff EC, Boormans JL.

PLoS One. 2017 Mar 20;12(3):e0174039. doi: 10.1371/journal.pone.0174039. eCollection 2017.

9.

FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.

Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC.

J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31.

PMID:
28049011
10.

Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.

van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, Dyrskjøt L, Márquez M, Ørntoft TF, Real FX, Segersten U, Malats N, Malmström PU, Van Criekinge W, Zwarthoff EC.

J Urol. 2017 Mar;197(3 Pt 1):590-595. doi: 10.1016/j.juro.2016.09.118. Epub 2016 Oct 13.

PMID:
27746284
11.

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.

Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA.

Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Review.

PMID:
27641313
12.

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.

Critelli R, Fasanelli F, Oderda M, Polidoro S, Assumma MB, Viberti C, Preto M, Gontero P, Cucchiarale G, Lurkin I, Zwarthoff EC, Vineis P, Sacerdote C, Matullo G, Naccarati A.

Oncotarget. 2016 Oct 11;7(41):67435-67448. doi: 10.18632/oncotarget.11883.

13.

Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer.

van Kessel KE, de Haan LM, Fransen van de Putte EE, van Rhijn BW, de Wit R, van der Heijden MS, Zwarthoff EC, Boormans JL.

Bladder Cancer. 2016 Jul 27;2(3):351-360.

14.

Limited Funds for Bladder Cancer Research and What Can We Do About It.

Boormans JL, Zwarthoff EC.

Bladder Cancer. 2016 Jan 28;2(1):49-51.

15.

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.

16.

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.

Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, Brand K, Dakna M, Roubelakis MG, Theodorescu D, Vlahou A, Mischak H, Anagnou NP.

Clin Cancer Res. 2016 Aug 15;22(16):4077-86. doi: 10.1158/1078-0432.CCR-15-2715. Epub 2016 Mar 29.

17.

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer.

Poyet C, Hermanns T, Zhong Q, Drescher E, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ.

Oncol Lett. 2015 Nov;10(5):2753-2760. Epub 2015 Sep 9.

18.

Editorial Comment.

van Kessel KE, Zwarthoff EC.

Urology. 2015 Dec;86(6):1190-1. doi: 10.1016/j.urology.2015.07.037. No abstract available.

PMID:
26719118
19.

Targeted therapies in bladder cancer: an overview of in vivo research.

van Kessel KE, Zuiverloon TC, Alberts AR, Boormans JL, Zwarthoff EC.

Nat Rev Urol. 2015 Dec;12(12):681-94. doi: 10.1038/nrurol.2015.231. Epub 2015 Sep 22. Review.

PMID:
26390971
20.

Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria.

van Kessel KE, Van Neste L, Lurkin I, Zwarthoff EC, Van Criekinge W.

J Urol. 2016 Mar;195(3):601-7. doi: 10.1016/j.juro.2015.08.085. Epub 2015 Aug 29.

PMID:
26327355
21.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward?

Zuiverloon TC, Zwarthoff EC.

Eur Urol. 2016 Feb;69(2):201-2. doi: 10.1016/j.eururo.2015.07.010. Epub 2015 Jul 21. No abstract available.

PMID:
26209036
22.

Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.

Geels YP, van der Putten LJ, van Tilborg AA, Lurkin I, Zwarthoff EC, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Visscher DW, Dowdy SC, Massuger LF.

Gynecol Oncol. 2015 May;137(2):245-51. doi: 10.1016/j.ygyno.2015.03.007. Epub 2015 Mar 12.

PMID:
25773202
23.

Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.

van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, Kirkels WJ, Zwarthoff EC, Boevé ER, Jöbsis AC, Bapat B, Jewett MA, Zlotta AR, van der Kwast TH.

Mod Pathol. 2015 May;28(5):695-705. doi: 10.1038/modpathol.2014.154. Epub 2014 Nov 28.

24.

Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer.

Beukers W, Kandimalla R, Masius RG, Vermeij M, Kranse R, van Leenders GJ, Zwarthoff EC.

Mod Pathol. 2015 Apr;28(4):515-22. doi: 10.1038/modpathol.2014.145. Epub 2014 Nov 14.

25.

Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.

Koopmans AE, Ober K, Dubbink HJ, Paridaens D, Naus NC, Belunek S, Krist B, Post E, Zwarthoff EC, de Klein A, Verdijk RM; Rotterdam Ocular Melanoma Study Group.

Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):6024-30. doi: 10.1167/iovs.14-14901.

PMID:
25159205
26.

TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.

Dubbink HJ, Bakels H, Post E, Zwarthoff EC, Verdijk RM.

J Neurooncol. 2014 Nov;120(2):267-72. doi: 10.1007/s11060-014-1553-8. Epub 2014 Jul 18.

PMID:
25035100
27.

Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.

Papathomas TG, Oudijk L, Zwarthoff EC, Post E, Duijkers FA, van Noesel MM, Hofland LJ, Pollard PJ, Maher ER, Restuccia DF, Feelders RA, Franssen GJ, Timmers HJ, Sleijfer S, de Herder WW, de Krijger RR, Dinjens WN, Korpershoek E.

Endocr Relat Cancer. 2014 Aug;21(4):653-61. doi: 10.1530/ERC-13-0429. Epub 2014 Jun 20.

PMID:
24951106
28.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

29.

Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.

Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C.

Eur Urol. 2015 Apr;67(4):729-37. doi: 10.1016/j.eururo.2014.04.014. Epub 2014 May 2. Review.

PMID:
24836153
30.

Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics.

Rau TT, Agaimy A, Gehoff A, Geppert C, Jung K, Knobloch K, Langner C, Lugli A, Groenbus-Lurkin I, Nagtegaal ID, Rüschoff J, Saegert X, Sarbia M, Schneider-Stock R, Vieth M, Zwarthoff EC, Hartmann A.

Virchows Arch. 2014 Jun;464(6):663-72. doi: 10.1007/s00428-014-1569-7. Epub 2014 Apr 12.

PMID:
24728704
31.

Absence of TERT promoter mutations in esophageal adenocarcinoma.

van Nistelrooij AM, Zwarthoff EC, Post E, Lurkin I, van Marion R, Korpershoek E, Biermann K, Wijnhoven BP, Dinjens WN.

Int J Cancer. 2014 Apr 15;134(8):2014-5. No abstract available. Erratum in: Int J Cancer. 2014 Nov 1;135(9):E8. Kopershoek, E [corrected to Korpershoek, E].

32.

Epidermal nevus in association with some uncommon manifestations.

Rostami P, Mahmoudi E, Sotoudeh A, Nakhaeimoghadam M, Lurkin I, Zwarthoff EC, Rezaei N.

Acta Dermatovenerol Croat. 2013;21(4):268-70. No abstract available.

PMID:
24476618
33.

HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome.

Beukers W, Hercegovac A, Zwarthoff EC.

Eur J Hum Genet. 2014 Jun;22(6):837-9. doi: 10.1038/ejhg.2013.251. Epub 2013 Oct 30.

34.

The use of molecular analyses in voided urine for the assessment of patients with hematuria.

Beukers W, Kandimalla R, van Houwelingen D, Kovacic H, Chin JF, Lingsma HF, Dyrskjot L, Zwarthoff EC.

PLoS One. 2013 Oct 15;8(10):e77657. doi: 10.1371/journal.pone.0077657. eCollection 2013.

35.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.

Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7.

PMID:
24018021
36.

A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.

Kandimalla R, Masius R, Beukers W, Bangma CH, Orntoft TF, Dyrskjot L, van Leeuwen N, Lingsma H, van Tilborg AA, Zwarthoff EC.

Clin Cancer Res. 2013 Sep 1;19(17):4760-9. doi: 10.1158/1078-0432.CCR-12-3276. Epub 2013 Jul 10.

37.

DNA methylation-based biomarkers in bladder cancer.

Kandimalla R, van Tilborg AA, Zwarthoff EC.

Nat Rev Urol. 2013 Jun;10(6):327-35. doi: 10.1038/nrurol.2013.89. Epub 2013 Apr 30. Review.

PMID:
23628807
38.

Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.

Bangma CH, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, Van Der Keur KA, Tjin S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ.

Eur Urol. 2013 Jul;64(1):41-7. doi: 10.1016/j.eururo.2013.02.036. Epub 2013 Mar 4.

PMID:
23478169
39.

Hypermethylation of the polycomb group target gene PCDH7 in bladder tumors from patients of all ages.

Beukers W, Hercegovac A, Vermeij M, Kandimalla R, Blok AC, van der Aa MM, Zwarthoff EC, Zuiverloon TC.

J Urol. 2013 Jul;190(1):311-6. doi: 10.1016/j.juro.2013.01.078. Epub 2013 Jan 28.

PMID:
23369722
40.

Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.

Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, Orntoft TF, Zwarthoff EC.

J Urol. 2013 May;189(5):1945-51. doi: 10.1016/j.juro.2012.11.115. Epub 2012 Nov 28.

PMID:
23201384
41.

FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.

van Kessel KE, Kompier LC, de Bekker-Grob EW, Zuiverloon TC, Vergouwe Y, Zwarthoff EC, Steyerberg EW.

J Urol. 2013 May;189(5):1676-81. doi: 10.1016/j.juro.2012.11.005. Epub 2012 Nov 6.

PMID:
23142690
42.

The leukemia-associated fusion protein MN1-TEL blocks TEL-specific recognition sequences.

ter Haar WM, Meester-Smoor MA, van Wely KH, Schot CC, Janssen MJ, Geverts B, Bonten J, Grosveld GC, Houtsmuller AB, Zwarthoff EC.

PLoS One. 2012;7(9):e46085. doi: 10.1371/journal.pone.0046085. Epub 2012 Sep 26.

43.

Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood.

van Tilborg AA, Kompier LC, Lurkin I, Poort R, El Bouazzaoui S, van der Keur K, Zuiverloon T, Dyrskjot L, Orntoft TF, Roobol MJ, Zwarthoff EC.

PLoS One. 2012;7(8):e43345. doi: 10.1371/journal.pone.0043345. Epub 2012 Aug 22.

44.

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?

Beukers W, Meijer T, Vissers CJ, Boormans JL, Zwarthoff EC, van Leenders GJ.

Virchows Arch. 2012 Aug;461(2):149-56. doi: 10.1007/s00428-012-1277-0. Epub 2012 Jul 10.

45.

Keratinocytic epidermal nevi are associated with mosaic RAS mutations.

Hafner C, Toll A, Gantner S, Mauerer A, Lurkin I, Acquadro F, Fernández-Casado A, Zwarthoff EC, Dietmaier W, Baselga E, Parera E, Vicente A, Casanova A, Cigudosa J, Mentzel T, Pujol RM, Landthaler M, Real FX.

J Med Genet. 2012 Apr;49(4):249-53. doi: 10.1136/jmedgenet-2011-100637.

PMID:
22499344
46.

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.

van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, van der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Bapat B, van der Kwast TH, Zlotta AR.

BJU Int. 2012 Oct;110(8):1169-76. doi: 10.1111/j.1464-410X.2012.10996.x. Epub 2012 Mar 27.

47.

KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.

Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJ, Thunnissen E, Zwarthoff EC.

J Mol Diagn. 2012 May-Jun;14(3):247-55. doi: 10.1016/j.jmoldx.2012.01.011. Epub 2012 Mar 14.

PMID:
22425762
48.

Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.

Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, Zwarthoff EC.

Eur Urol. 2012 Jun;61(6):1245-56. doi: 10.1016/j.eururo.2012.01.011. Epub 2012 Jan 18.

PMID:
22284968
49.

A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients.

Fernandez CA, Millholland JM, Zwarthoff EC, Feldman AS, Karnes RJ, Shuber AP.

Res Rep Urol. 2012 Mar 5;4:17-26. doi: 10.2147/RRU.S28959. eCollection 2012.

50.

The FGFR3 mutation is related to favorable pT1 bladder cancer.

van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B.

J Urol. 2012 Jan;187(1):310-4. doi: 10.1016/j.juro.2011.09.008. Epub 2011 Nov 17.

PMID:
22099989

Supplemental Content

Loading ...
Support Center